Phaseline

Companies › Ashvattha Therapeutics

Ashvattha Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Other, Neurology, Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Aflibercept (D-4517)
Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor
VEGFA, PGFPhase 2Neovascular Age-related Macular Degeneration–
18F-OP-801
Biomarker for PET imaging of activated microglia and macrophages
–Phase 1Amyotrophic Lateral Sclerosis (ALS)–
MGB (Migaldendranib)–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05387837Aflibercept (D-4517)Phase 2Neovascular Age-related Macular DegenerationOphthalmologyMay 2025
NCT0539562418F-OP-801Phase 1Amyotrophic Lateral Sclerosis (ALS)NeurologyJan 2026
NCT07370155MGB (Migaldendranib)Phase 1Healthy VolunteersOtherMar 2026

Targets

VEGFA (1) PGF (1)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Regeneron Pharmaceuticals Samsung Bioepis Biotheus AstraZeneca Prestige Biopharma Avirmax Biopharma Eli Lilly

Companies built like this

EnnovaBio Design Therapeutics Samsung Bioepis Centessa Pharmaceuticals (UK) H. Lundbeck

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.